Share the Video:

Addressing Myths and Misconceptions about MDMA Assisted Therapy: Part 1

PS2025MDMAPsychedelic Assisted Therapy

Kelley O’Donnell, Amy Lehrner, Chantelle Thomas, Casey Paleos, Genesee Herzberg, Marcela Ot’alora, M.F.T.

As MDMA-assisted therapy moved toward regulatory approval in 2024, misinformation and oversimplifications shaped public, professional, and regulatory discourse on the topic. Today, misunderstandings about the form of MDMA-assisted therapy provided in the Phase 3 trials persist. This panel brings together leading clinician-researchers to address key myths and misconceptions about the content, process, and safety of this treatment. This discussion, Part 1 of a two-part exploration of these themes (Part 2: Doblin Stage, 6/20), will focus on the practice and teaching of MDMA-assisted therapy, identifying and correcting misunderstandings about the therapeutic process and the theoretical framework that supports it.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos

PS2023MDMAPsychedelic Assisted TherapyResearch

Investigational MDMA-assisted therapy and eating disorder symptoms in a randomized placebo-controlled trial for severe PTSD

MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.

Adele LaFrance, Timothy Brewerton

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyResearchResources for Therapists

Being a Psychedelic Therapist

Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.

Norma Stevens

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelics as The Great Disrupters: Reconstructing the Future of Mental Healthcare

Dr. Ben Sessa will discuss similarities among MDMA, ketamine, and psilocybin in clinical settings, exploring their potential in treating trauma-based disorders and challenges in psychedelic medicalization.

Ben Sessa

PS2023MDMAPolicy and AdvocacyPsychedelic Assisted TherapyPsychedelic SciencePublic BenefitResearch

Preview Scene from Prescription X: The Rick Doblin and MAPS Documentary (Work in Progress)

"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.

Nirvan Mullick, Dream Mullick

PS2023Healing for AllKetamineMDMAPsychedelic Assisted TherapyPsychedelic ScienceSocial and Cultural

Rave as Ritual: The Intersection of Collective Movement and Entheogens

Rave culture and electronic music are modern forms of ritual that tap into primal instincts, offering potential for social bonding, trauma processing, and expanded awareness through movement and psychedelics.

Taylor Bratches

PS2023MDMAPsychedelic Assisted TherapyResearch

Unlocking the Healing Potential: A Conversation on Experiential Training in MDMA-Assisted Therapy with Payton Nyquvest and Rick Doblin

Payton Nyquvest and Rick Doblin discuss MDMA-Assisted Therapy's transformative potential for healing and mental health in an insightful panel discussion.

PS2023Health ConditionsMDMAPsychedelic Assisted TherapyPsychedelic ScienceResearchTherapy Ethics

Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine

MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.

Matthew Baggott

PS2023MDMAMDMA-assisted therapyPsychedelic Assisted TherapyPTSDResearch

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.

Keren Tzarfaty, Michael Mithoefer, Julie Holland

PS2023MDMAPsychedelic Assisted TherapyPsychedelic ScienceResearch

Grounding Psychedelic Research in Memory for Advancing Psychedelic Drug Discovery

M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.

James Keim